Journal of addiction medicine
A Long-acting Naltrexone Implant (iSTEP-N) for Opioid Use Disorder: First-in-Human Phase I Trial.
Steven M Cohen, Jeffrey Benner, Pravin Soni, William R Ravis, Todd Bertoch, Janet Ransom, Jonathan Berman
Published: 202610.1097/ADM.0000000000001654
Abstract
OBJECTIVES: iSTEP-N is a novel, bioresorbable, subcutaneous implant designed to release naltrexone for 6-12 months after a single procedure and improve adherence. This first-in-human study evaluated the safety and pharmacokinetics of iSTEP-N. METHODS…
Preview only. Read the full abstract at the source